



# Vismodegib

**Catalog No: tcsc0255** 



Size: 100mg

## **Available Sizes**

Size: 10mg			
Size: 50mg			

Size: 200mg			

Size: 500mg	

Size: 1g	

Size: 2g		

Size: 5g



# **Specifications**

**CAS No:** 879085-55-9

Formula:  ${\rm C}_{19}{\rm H}_{14}{\rm CI}_2{\rm N}_2{\rm O}_3{\rm S}$ 

**Pathway:** Stem Cell/Wnt; Autophagy

**Target:** Hedgehog; Autophagy **Purity / Grade:** 

>98%

**Solubility:** 





H20:

#### **Alternative Names:**

GDC-0449

### **Observed Molecular Weight:**

421.3

# **Product Description**

Vismodegib is an orally active **hedgehog** pathway inhibitor with an  $IC_{50}$  of 3 nM and also inhibits P-gp, ABCG2 with  $IC_{50}$  values of 3.0  $\mu$ M and 1.4  $\mu$ M, respectively.

IC50 & Target: IC50: 3 nM (hedgehog), 3.0 μM (P-gp), 1.4 μM (ABCG2)

In Vitro: Vismodegib (HhAntag691) is an ABCG2 inhibitor and can increase the effective intracellular concentration of mitoxantrone, another ABCG2 substrate, through blocking its export in HEK293 cells. Vismodegib (HhAntag691, 10  $\mu$ M), resensitizes MDCKII/Pgp cells and MDCKII/MRP1 cells to colchicine treatment<sup>[2]</sup>. Vismodegib (25  $\mu$ M or 50  $\mu$ M) concentration dependently inhibits HCC and H1339 cells<sup>[3]</sup>.

In **Vivo:** Vismodegib is a novel small molecule HPI, often used for clinical trials<sup>[1]</sup>. Vismodegib (0.3 to 75 mg/kg, p.o.) is highly efficacious in medulloblastoma allograft tumors. Vismodegib (> 46 mg/kg, p.o.) causes growth delay in patient-derived colorectal xenografts<sup>[4]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!